Live Breaking News & Updates on Mbrx

Stay informed with the latest breaking news from Mbrx on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Mbrx and stay connected to the pulse of your community

Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a report released on Sunday morning. The brokerage issued a sell rating on the stock. Other analysts have also recently issued research reports about the company. Maxim Group cut their target price on Moleculin Biotech from $45.00 to $20.00 and set a […]

Roth-mkm , Nasdaq , Moleculin-biotech-inc , Atticus-wealth-management , Exchange-commission , Maxim-group , Moleculin-biotech , Free-report , Wealth-management , Get-free-report , Moleculin-biotech-daily , Nasdaq-mbrx

Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Get Free Report) in a report released on Friday. The brokerage set a “sell” rating on the stock. Several other brokerages also recently weighed in on MBRX. Maxim Group decreased their target price on Moleculin Biotech from $45.00 to $20.00 and set […]

Renaissance-technologies , Armistice-capital , Maxim-group , Moleculin-biotech-inc , Charles-schwab-investment-management-inc , Citadel-advisors , Moleculin-biotech , Get-free-report , Biotech-trading-down , Street-corp , Schwab-investment-management

StockNews.com Initiates Coverage on Moleculin Biotech (NASDAQ:MBRX)

Research analysts at StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Get Free Report) in a report issued on Thursday. The brokerage set a “sell” rating on the stock. A number of other equities analysts also recently commented on MBRX. HC Wainwright reiterated a “buy” rating and set a $45.00 target price on […]

Maxim-group , Moleculin-biotech-inc , Citadel-advisors , Atticus-wealth-management , Charles-schwab-investment-management-inc , Renaissance-technologies , Moleculin-biotech , Get-free-report , Schwab-investment-management , Wealth-management , State-street-corp

Moleculin Biotech (NASDAQ:MBRX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a report published on Saturday. The firm issued a sell rating on the stock. Separately, HC Wainwright restated a buy rating and set a $3.00 target price on shares of Moleculin Biotech in a research note on Thursday, December 14th. View Our […]

Walterv-klemp , Renaissance-technologies , Securities-exchange-commission , Moleculin-biotech-inc , Citadel-advisors , Charles-schwab-investment-management-inc , Atticus-wealth-management , Armistice-capital , Moleculin-biotech , Free-report , Exchange-commission

Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research report sent to investors on Saturday morning. The brokerage issued a sell rating on the stock. Separately, HC Wainwright reissued a buy rating and set a $3.00 target price on shares of Moleculin Biotech in a research note on Thursday, […]

Walterv-klemp , Nasdaq , Charles-schwab-investment-management-inc , Renaissance-technologies , Moleculin-biotech-inc , Citadel-advisors , Securities-exchange-commission , Atticus-wealth-management , Moleculin-biotech , Free-report , Exchange-commission

StockNews.com Initiates Coverage on Moleculin Biotech (NASDAQ:MBRX)

Stock analysts at StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Get Free Report) in a research report issued to clients and investors on Saturday. The brokerage set a “sell” rating on the stock. Separately, HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of Moleculin Biotech in […]

Walterv-klemp , Charles-schwab-investment-management-inc , Moleculin-biotech-inc , Citadel-advisors , Atticus-wealth-management , Renaissance-technologies , Moleculin-biotech , Get-free-report , Biotech-stock-down , Schwab-investment-management , Wealth-management

Moleculin Biotech (NASDAQ:MBRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research report report published on Thursday. The firm issued a sell rating on the stock. Separately, HC Wainwright reaffirmed a buy rating and set a $3.00 price objective on shares of Moleculin Biotech in a research report on Thursday, December 14th. […]

Walterv-klemp , Atticus-wealth-management , Renaissance-technologies , Moleculin-biotech-company-profile , Charles-schwab-investment-management-inc , Nasdaq , Moleculin-biotech-inc , Moleculin-biotech , Free-report , Biotech-stock-down , Get-free-report

Roth Capital Equities Analysts Lift Earnings Estimates for Moleculin Biotech, Inc. (NASDAQ:MBRX)

Moleculin Biotech, Inc. (NASDAQ:MBRX – Free Report) – Roth Capital upped their Q4 2023 EPS estimates for Moleculin Biotech in a research note issued on Wednesday, January 24th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings per share of ($0.19) for the quarter, up from their previous estimate of ($0.20). […]

Walterv-klemp , Securities-exchange-commission , Moleculin-biotech-company-profile , Charles-schwab-investment-management-inc , Moleculin-biotech-inc , Renaissance-technologies , Nasdaq , Atticus-wealth-management , Moleculin-biotech , Free-report , Roth-capital

StockNews.com Begins Coverage on Moleculin Biotech (NASDAQ:MBRX)

StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research report released on Wednesday. The brokerage issued a sell rating on the stock. Separately, HC Wainwright reissued a buy rating and issued a $3.00 price objective on shares of Moleculin Biotech in a research note on Thursday, December 14th. Get […]

Walterv-klemp , Moleculin-biotech-inc , Atticus-wealth-management , Moleculin-biotech-company-profile , Charles-schwab-investment-management-inc , Securities-exchange-commission , Renaissance-technologies , Moleculin-biotech , Free-report , Get-free-report , Exchange-commission

StockNews.com Begins Coverage on Moleculin Biotech (NASDAQ:MBRX)

StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a report published on Wednesday. The firm issued a sell rating on the stock. Separately, HC Wainwright reiterated a buy rating and set a $3.00 target price on shares of Moleculin Biotech in a research note on Thursday, December 14th. Get Our […]

Walterv-klemp , Renaissance-technologies , Moleculin-biotech-inc , Moleculin-biotech-company-profile , Nasdaq , Charles-schwab-investment-management-inc , Atticus-wealth-management , Moleculin-biotech , Free-report , Get-free-report , Schwab-investment-management